19th week of 2009 patent applcation highlights part 48 |
Patent application number | Title | Published |
20090118300 | Substituted Imidazole 4-Carboxamides as Cholecystokinin-1 Receptor Modulators - Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes. | 2009-05-07 |
20090118301 | Compositions and Methods for Treating Cancer - The invention provides compounds useful for treating or effecting prophylaxis of cancers, particularly cervical cancer. | 2009-05-07 |
20090118302 | Novel Benzopyran Derivatives Having Inhibitory Activities Against Liver Fibrosis and Cirrhosis and Their Pharmaceutical Uses - The present invention relates to a novel benzopyran derivative having goodantagonistic activity on TGF-β receptor which can be effectively used as a prophylactic and therapeutic agent for liver disease as well as several fibroplasiadiseases such as hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, dermatosclerosis, glomerular fibrosis and the like; and a pharmaceutical use thereof. | 2009-05-07 |
20090118303 | SEROTONIN 5-HT3 RECEPTOR AGONIST - A serotonin 5-HT3 receptor agonist containing a compound represented by the general formula (1) [R | 2009-05-07 |
20090118304 | 2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE - Disclosed is a compound represented by the formula (I) below, which has a glucokinase-activating effect and is thus useful for treatment of diabetes or obesity, or a pharmaceutically acceptable salt thereof. | 2009-05-07 |
20090118305 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 - The invention concerns pyridine and pyrazine derivatives of Formula I | 2009-05-07 |
20090118306 | Novel use of liver X receptor agonists - The present invention generally relates to a novel therapeutical use of liver X receptor (LXR) agonsits. More specifically, the present invention relates to the use of LXR agonist for the preparation of a medicament useful for the treatment and/or the prevention of a disease associated with beta cells degeneration, such as diabetes, and a method for increasing ex vivo viability of pancreatic islet cells, comprising contacting said islet cells with a LXR agonist. | 2009-05-07 |
20090118307 | Aryl Sulfonamides - Compounds are provided that act as potent antagonists of the CCR9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists. | 2009-05-07 |
20090118308 | 2,2-Bis-(hydroxymethyl)cyclopropylidenemethyl-Purines and -Pyrimidines As Antiviral Agents - Compounds which are active against viruses have the following formulas: | 2009-05-07 |
20090118309 | Selective antagonists of A2A adenosine receptors - The present invention provides compounds of formulae Ia and Ib: | 2009-05-07 |
20090118310 | Activated Cdc42-associated kinase (ACK) as a therapeutic target for Ras-induced cancer - Methods for preventing or treating Ras-induced cancer in a patient by (a) detecting v-Ha-Ras-transformed cells in a patient and (b) administering to the patient a therapeutically effective amount of a chemotherapeutic composition comprising an effective amount of an inhibitor for activated Cdc42-associated kinase (ACK) kinase. | 2009-05-07 |
20090118311 | DHFR Enzyme Inhibitors - Compounds of formula (I) or (II) are dihydrofolate reductase inhibitors, useful for the treatment of, for example, cell proliferative diseases: | 2009-05-07 |
20090118312 | Macrocylic Inhibitors of Hepatitis C Virus - Compounds of the formula I: | 2009-05-07 |
20090118313 | Novel Compounds - Pyrimidone compounds of formula (I): | 2009-05-07 |
20090118314 | TUMOR SUPPRESSOR - A compound having a sructure of propanedioic acid represented by the following formula ( | 2009-05-07 |
20090118315 | Methods of Treatment Using Sapacitabine - A first aspect of the invention relates to a method of treating leukaemia or myelodysplastic syndromes (MDS), said method comprising administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, to a subject in accordance with a dosing regimen comprising at least one treatment cycle, wherein said treatment cycle comprises administering a therapeutically effective amount of sapacitabine, or a metabolite thereof, for 7 consecutive days every 21 days or 14 consecutive days every 21 days. | 2009-05-07 |
20090118316 | Methods for Augmenting Bone - The present invention relates to methods of stimulating osteoblast function with a PYK2 inhibitor in subjects with osteoporosis, bone fractures, non-unions, pseudoarthroses, periodontal disease or other disorders of bone metabolism. Optionally, the method further comprises administration of a second therapeutic bone agent. The present invention also relates to methods to identify a PYK2 inhibitor effective as a therapeutic bone agent comprising administering a test agent to an osteoblast-like cell and determining if osteoblast function is stimulated. Optionally, the identifying method further comprises contacting the test agent with PYK2 and determining if PYK2 activity is inhibited. | 2009-05-07 |
20090118317 | Statin-Carboxyalkylether Combinations - The invention is a pharmaceutical composition comprising a carboxyalkylether which lowers triglycerides and elevated HDL, and a statin which inhibits HMG-CoA reductase, thereby reducing LDL, said composition being useful for treating vascular diseases. | 2009-05-07 |
20090118318 | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases - The invention provides compounds of general formula wherein R and R | 2009-05-07 |
20090118319 | Fused and Spirocycle Compounds and the Use Thereof - The invention relates to fused and spirocycle compounds of Formula (I), or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein R | 2009-05-07 |
20090118320 | DERIVATIVES OF 5,9-METHANOCYCLOOCTA[B]PYRIDIN-2-(1H)-ONE, THEIR PREPARATION AND USE AS ANALGESICS - A compound of Formula I, a pharmaceutically-acceptable salt or a hydrate thereof, wherein R | 2009-05-07 |
20090118321 | 5-Urea Substituted Naphthalimide Derivatives, Methods of Production and Pharmaceutical Compositions for Treating Cancer - Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods for making such derivatives through hydrolysis of known compounds. | 2009-05-07 |
20090118322 | Agent for repairing corneal sensitivity containing amide compound - The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye. | 2009-05-07 |
20090118323 | ANTITUMOR BENZOYLSULFONAMIDES - The present invention provides antitumor compounds of the formula (I); and antitumor methods. | 2009-05-07 |
20090118324 | MAPK/ERK KINASE INHIBITORS - Compounds are provided for use with MEK that comprise: | 2009-05-07 |
20090118325 | 5-Thioxylopyranose Compounds - 5-thioxylose compounds, especially 5-thioxylopyranose compounds, a process for their preparation, and their use for treating and/or inhibiting thromboses, especially venous thromboses. The compounds correspond to formula I: | 2009-05-07 |
20090118326 | Nicotinic Acetylcholine Receptor Modulators - The disclosure provides compounds capable of selectively or non-selectively modulating nicotinic acetylcholine receptors. The compounds, compositions, and methods described herein are useful, for example, in treating patients suffering from various medical conditions including pain, chemical addictions, Parkinson's disease, Alzheimer's disease, and neurodegenerative disorders. In one embodiment, the compounds comprise a 7- to 11-membered azabicyclo ring. | 2009-05-07 |
20090118327 | SUBSTITUTED 1-AMINO-4-PHENYL-DIHYDROISOQUINOLINES, METHODS FOR THE PRODUCTION THEREOF, USE THEREOF AS A MEDICAMENT, AND MEDICAMENTS CONTAINING THEM - The present invention relates to compounds useful in the prevention or treatment of various disorders such as acute or chronic renal failure, for impairments of biliary function, for respiratory impairments such as snoring or sleep apneas or for stroke, and pharmaceutical compositions comprising them. More specifically, the compounds of the present invention comprises substituted 1-amino-4-phenyl-dihydroisoquinolines and their derivatives of formula I: | 2009-05-07 |
20090118328 | Pharmaceutical Compositions Of Cholesteryl Ester Transfer Protein Inhibitors And Hmg-Coa Reductase - A solid amorphous dispersion comprises a cholesteryl ester transfer protein (CETP) inhibitor, an inhibitor of 3-hydroxy-3-methylglutaryl-conenzyme A reductase (HMG-CoA reductase inhibitor), and a concentration enhancing polymer. At least a major portion of the CETP inhibitor in the dispersion is amorphous. The solid amorphous dispersion provides concentration-enhancement of the CETP inhibitor when administered to an aqueous use environment. | 2009-05-07 |
20090118329 | Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use - The invention relates to NHE-3 inhibitor compounds of formula I: | 2009-05-07 |
20090118330 | Diurea derivatives - The present invention relates to novel diurea derivatives that block intracellular signal transduction and thereby inhibit the production of pro-inflammatory cytokines, especially interleukin-2 (IL-2) and/or induce apoptosis in activated T-cells. It further discloses such a compound for use as a medicament, the use of said compound for the manufacturing of a medicament for the treatment of immune disorders which benefit from inhibition of production of IL-2 and other pro-inflammatory cytokines and/or induction of apoptosis in activated T-cells, a pharmaceutical composition comprising said compound and a method of treatment comprising administration of a pharmaceutically effective amount of said compound. | 2009-05-07 |
20090118332 | Therapeutic Agents - 551 - A compound of formula I | 2009-05-07 |
20090118333 | AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2009-05-07 |
20090118334 | METHOD OF TREATMENT OF CARDIAC AND/OR RENAL FAILURE USING A CALCIUM CHANNEL BLOCKER AND AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR OR AN ANGIOTENSIN II RECEPTOR BLOCKER - A pharmaceutical composition including a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease by identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein to said patient. | 2009-05-07 |
20090118335 | Acid Secretion Inhibitor - The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like. | 2009-05-07 |
20090118336 | PYRAZOLE DERIVATIVES AND THEIR USE AS PI3K INHIBITORS - The invention concerns pyrazole derivatives of Formula I | 2009-05-07 |
20090118337 | Methods and compositions for treating inflammation - A method of treating a subject with a cystic fibrosis related disorder includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof. | 2009-05-07 |
20090118338 | ARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2009-05-07 |
20090118339 | LYSINE RELATED DERIVATIVES AS HIV ASPARTYL PROTEASE INHIBITORS - The present invention concerns lysine related derivatives, their use as protease inhibitors, in particular as HIV aspartyl protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present lysine related derivatives with another anti retroviral agent. It further relates to their use in assays as reference compounds or as reagents. | 2009-05-07 |
20090118340 | Method for inhibiting and/or preventing formation of cancer metastases and seconddary malignant cancers - The invention relates to a method for inhibiting and/or preventing formation of cancer metastases and secondary malignant cancers by administration to a subject of an effective amount of a quaternary pyridinium salt of formula I | 2009-05-07 |
20090118341 | Method for treatment of chronic neuropathic pain - Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors. | 2009-05-07 |
20090118342 | DESIGN AND SYNTHESIS OF BIOTINYLATED PROBES FOR N-ACYL-ETHANOLAMINES - The present invention relates to the synthesis and characterisation of biotinylated analogue of N-arachidonoylethanolamine (AEA) and its use as a tool to study AEA transport and trafficking through biochemical and morphological techniques. In particular biotinylated AEA (b-AEA, for which we propose the common name MM22) is suitable to design highly sensitive and simple methods for the non-radioactive detection and quantitation of AEA from complex samples, which would offer a useful alternative approach to the routinely used radiometric assays. The invention also relates to the use of b-AEA as a potential therapeutic and diagnostic agent. | 2009-05-07 |
20090118343 | TREATMENT OF SEVERE DISTAL COLITIS - This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided. | 2009-05-07 |
20090118344 | Crystalline Chemotherapeutic - N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed. | 2009-05-07 |
20090118345 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel pyrazoles that are useful as cannabinoid receptor antagonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, hepatic disorders, and/or cardiometabolic disorders. | 2009-05-07 |
20090118346 | Alkyl-Analide Producing Method - New pyrazolylcarboxanilides of the formula (I) | 2009-05-07 |
20090118347 | Method of Treating Down Syndrome - A method of, or the use of compounds of the invention for, treating the cognitive impairments associated with Down syndrome, the method or use comprising treating or administering to a person with an effective amount of phenserine and isomers thereof or a pharmaceutically acceptable salt and derivatives thereof. | 2009-05-07 |
20090118348 | DRUG-INTRODUCED PHOTO-CROSSLINKED HYALURONIC ACID DERIVED GEL - A drug-introduced photo-crosslinked hyaluronic acid derived gel which is a photo-crosslinked hyaluronic acid gel into which a drug is introduced through a covalent bond, and has characteristics that are capable of extruding from an injection device. The drug-introduced photo-cross-linked hyaluronic acid derived gel is capable of extruding, for example, by an injection needle of 20 to 25 gauge with a pressure of 0.5 to 5 kg/cm | 2009-05-07 |
20090118349 | BIS-ALKYLATING AGENTS AND THEIR USE IN CANCER THERAPY - The present invention relates to (i) conjugates comprising two DNA alkylating subunits linked by a moiety fitting to the minor groove of the DNA, (ii) to their preparation and (iii) to their use in cancer therapy. The alkylating subunits are especially cytotoxic under hypoxic conditions found in cancer cells. The compounds of the present invention and compositions thereof are useful in the treatment of cancer in a mammal, both alone or in a combination with other anti-cancer agents (e.g. checkpoint abrogators) and/or radiation. They may also be used as cytotoxic units for gene-directed enzyme-prodrug therapy (GDEPT) and antibody-directed enzyme-prodrug therapy (ADEPT). | 2009-05-07 |
20090118350 | Biomarkers for Identifying Efficacy of Tegaserod in Patients with Chronic Constipation - Pharmacogenetics was used to evaluate the effect of polymorphisms in select candidate genes on the response of patients with chronic constipation to tegaserod (Zelmac®/Zelnorm®). The analysis identified twelve single nucleotide polymorphisms (SNPs) in six genes (HTR4, HTR3B, MLN, AQP3, SLC12A2, SCNN1A) that were associated with at least a 60% response rate to tegaserod and an odds ratios of 5 or greater (compared to placebo) after 4 weeks of treatment. The identified genes display a wide range of different functions, including serotonin signaling, secretion and motility, all of which are important in maintaining the normal function of the gastrointestinal tract. Thus, these data imply that chronic constipation may result from a variety of pathophysiological mechanisms related to variants in the above identified genes, all of which respond well to treatment with tegaserod. Patients without these variants do not respond to treatment significantly more than they do to placebo, which could indicate that their chronic constipation is not due to pathophysiological mechanisms but rather to environmental or possibly psychological factors. Patients with these variants are also less likely to respond to placebo, again implying that these variants are associated with a true pathophysiology. | 2009-05-07 |
20090118351 | Angiotensin I-Converting Enzyme (ACE) Inhibitors - This invention relates to a process for synthesising an amino acid derivative of a tripeptidomimetic, such as lisinopril. The invention also relates to a derivative of lisinopril, incorporating a amino acid moeity such as tryptophan at the P2′ position. | 2009-05-07 |
20090118353 | Medicinal composition - The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT | 2009-05-07 |
20090118354 | Liquid Pharmaceutical Formulations of Docetaxel - There is provided a liquid pharmaceutical formulation for parenteral administration comprising: docetaxel or a pharmaceutically acceptable salt thereof; one or more glycols; and a pharmaceutically acceptable nonaqueous solvent system; wherein the formulation has a pH meter reading in the range of from 2.5 to 7. | 2009-05-07 |
20090118355 | Fluorotaxoids - The invention relates to fluorinated second generation taxoid compounds, pharmaceutical formulations thereof, and their use for inhibiting the growth of cancer cells in a mammal. | 2009-05-07 |
20090118356 | NEO-TANSHINLACTONE AND ANALOGS AS POTENT AND SELECTIVE ANTI-BREAST CANCER AGENTS - Compounds of Formulas I-II are described, | 2009-05-07 |
20090118357 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field - Therefore the present invention relates specifically to the compounds of general formula (I), in which R | 2009-05-07 |
20090118358 | Kainate Receptor-Selective Epimeric Analogs of Dysiherbaine - Disclosed are compounds, pharmaceutical compositions, methods of treatment, and methods for selectively antagonizing a GluR5 receptor, a GluR6 receptor, or both receptors. The pharmaceutical compositions include and the methods utilize compounds that are analogs and stereoisomers of dysiherbaine and neodysiherbaine which have specificity for kainate receptors. | 2009-05-07 |
20090118359 | Food product - A method for the treatment of a bioflavonoid composition, comprising the contacting of the bioflavonoid composition with ethanol of at least 90% purity at a temperature of from 10 to 80° C. for a period of at least 0.5 hour, followed by separation of the ethanol and the bioflavonoid, wherein the contacting comprises the solubilisation of the bioflavonoid in the ethanol and whereby the separation involves the recrystallisation of the bioflavonoid and whereby the contacting takes place in the presence of active carbon in an amount of 1-10 wt % based on the bioflavonoid. | 2009-05-07 |
20090118360 | Process for manufacturing leaf tea - Disclosed is a process comprising the steps of: expressing juice from fresh tea leaves thereby to produce leaf residue and tea juice wherein the amount of expressed juice is greater than 300 ml per kg of fresh tea leaves; subjecting the fresh tea leaves and/or the leaf residue to an enzyme deactivation treatment thereby to prevent fermentation of the leaf residue; and drying the leaf residue to produce leaf tea. Also disclosed is a leaf tea obtained by the process. | 2009-05-07 |
20090118361 | SUPPRESSOR OF EXPRESSION OF MCP-1, AND AMELIORATING AGENT FOR INFLAMMATORY DISEASE, PHARMACEUTICAL, SUPPLEMENT, FOOD, BEVERAGE OR FOOD ADDITIVE USING THE SUPPRESSOR - A suppressor of the expression of MCP-1 is provided that is excellent in safety and is widely applicable to, for example, foods. The suppressor of the expression of MCP-1 according to the present invention is characterized by containing auraptene. Auraptene is contained in citrus fruits such as Hassaku, Amanatsu, Natsumikan, and grapefruit. Since these citrus fruits have been eaten for a long time, the present invention has no problem in safety. Furthermore, even when added to, for example, foods, auraptene does not impair the flavor thereof because it is substantially tasteless and odorless. Since auraptene has a low calorific value, for example, an obese person or a diabetic patient can ingest it over a long period of time. Auraptene suppresses the expression of MCP-1 at a genetic level (see FIG. | 2009-05-07 |
20090118362 | CHEMOTHERAPEUTIC AGENTS FOR INHIBITION OF PROTEIN TRANSLATION - The present invention relates to a anti-proliferative target for designing chemotherapeutic agents, which comprises a EIF4A protein having an amino acid sequence, as defined in claim | 2009-05-07 |
20090118363 | SESAMIN-CLASS COMPOUND-CONTAINING FOODS OR BEVERAGES FOR ANIMALS - Methods for treating coats and/or body odors of animals are provided. Foods and beverages for nonhuman animals that can be used in the methods are provided. | 2009-05-07 |
20090118364 | Novel diterpenes from the fruiting body of antrodia camphorata and pharmaceutical compositions thereof - The present invention relates to novel diterpene compounds isolated from the fruiting body of | 2009-05-07 |
20090118365 | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain - Methods of treating neuropathic pain, musculoskeletal pain, and back spasm associated with musculoskeletal pain in a patient comprising orally administering a therapeutically effective dose of a prodrug of a GABA | 2009-05-07 |
20090118366 | ORGANIC COMPOUNDS - A compound of formula (I) | 2009-05-07 |
20090118367 | INSECTICIDAL COMPOSITIONS WITH DISINFECTANT - Insecticidal compositions having insecticide and disinfectant activity are provided. Preferably, the insecticidal composition contains both an insect control agent and a disinfectant. Particularly low levels (i.e., below 20%) of at least one hydrocarbon are introduced as a solvent. The insecticidal compositions further comprise an emulsifier, buffer and antifoaming agent. These insecticidal compositions are particularly suitable for delivery in a spray for non-industrial environments. In use, the present insecticidal compositions may be applied directly to or in or around any area where it is desired to control pestiferous insects and the fungi, bacteria, viruses and other contaminants associated with them. | 2009-05-07 |
20090118368 | COMPOUNDS FOR INHIBITION OF 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE REUPTAKE OR FOR TREATMENT OF DEPRESSION DISORDERS, THEIR PREPARATION PROCESSES AND USES THEREOF - The present invention discloses compounds of formula (I), their optical isomers or pharmaceutically acceptable salts thereof, their preparation and uses thereof, wherein the definitions of R1, R2, R3 and R4 are shown in the description. These compounds are optical isomers or racemic mixtures. After these compounds are uptaken, they are metabolically transformated in vivo into 1-[2-dimethylamino-1-(4-hydroxyphenyl)-ethyl]-cyclohexanol that has neuropharmacological activity, by interrupting reuptake of 5-hydroxytryptamine (5-HT) and/or norepinephrine (NA), which is used for treating diseases associated with central nerve system, such as depression, etc. | 2009-05-07 |
20090118369 | Use of CIS-9, Trans-11 Isomer of Conjugated Lineoleic Acid - A composition and medicament comprising the cis-9, trans-11 isomer of conjugated linoleic acid for treating inflammatory diseases, including asthma, is provided. A method for inhibiting the proliferation of human or animal cells of the immune systems involved in an immune response including administering the cis-9, trans-11 isomer of conjugated linoleic acid to a patient is also provided. A nutritional, functional food, or dietary supplement including the cis-9, trans-11 isomer of conjugated linoleic acid is also provided. | 2009-05-07 |
20090118370 | METHOD OF TREATING CANCER USING DICHLOROACETATE - The invention relates to the use of dichloroacetate and chemical equivalents thereof for the treatment of cancer by inducing apoptosis or reversing apoptosis-resistance in a cell Preferably, the dosage is 10-100 mg/kg Preferably, sodium dichloroacetate is used. The dichloroacetate may optionally be given in combination with a pro-apoptotic agent and/or a chemotherapeutic agent Preferably, the cancers treated are non-small cell lung cancer, glioblastoma and breast carcinoma. | 2009-05-07 |
20090118371 | Delta 6 Desaturase From Thraustochytrid and its Uses Thereof - The present invention is directed to an isolated delta-6 desaturase gene from Schizochytrium. It is further directed to the cloning of delta-6 desaturase derived from Schizochytrium in Yeast. The nucleic acid sequence and the amino acid sequences of the delta-6 desaturase are disclosed. Further disclosed are the constructs, vector comprising the gene encoding the enzyme delta-6 desaturase in functional combination with the heterologous regulatory sequences. The novel delta-6 desaturase can be used in a metabolic pathway to convert linoleic acid to gamma linolenic acid (omega-6 pathway). The invention provides the identification, isolation of these novel nucleic acids from Schizochytrium that encode the above-mentioned proteins. The invention specifically exemplifies recombinant yeast cells harboring the vector comprising the delta-6 desaturase gene and by the virtue of the enzyme produced shall be able to produce gamnia-linolenic acid. | 2009-05-07 |
20090118372 | Inhibitors Of Biotin Protein Ligase - The present invention relates to a method for identifying an inhibitor of a biotin protein ligase. The method include the steps of (a) providing a substrate, wherein the substrate may be biotinylated; (b) contacting the substrate with biotin and a biotin protein ligase in the presence of a test compound; (c) determining the extent of biotinylation of the substrate by the biotin protein ligase in the presence of the test compound; and (d) identifying the test compound as an inhibitor of the biotin protein ligase by a reduction in the biotinylation of the substrate in the presence of the test compound as compared to the extent of biotinylation of the substrate in the absence of the test compound. | 2009-05-07 |
20090118373 | Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops - A natural formulation of compounds isolated or derived from hops which inhibit the activity of cyclooxygenase-2 (COX-2) and/or 5-lipoxygenase (5-LOX) is disclosed. The hops formulations may be administered to a mammal to treat or inhibit a pathological condition associated with the activity of COX-2 and/or 5-LOX in such a mammal. | 2009-05-07 |
20090118374 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR - The invention relates to sulfonamido derivatives of formula (I) | 2009-05-07 |
20090118375 | Optically active phthalamides - Novel optically active phthalamides of the formula (I) in which A, q, R | 2009-05-07 |
20090118376 | Memantine Protects Inflammation-Related Degeneration of Dopamine Neurons Through Inhibition of Over-Activated Microglia and Release of Neurotrophic Factors from Astroglia - This invention discloses that memantine (MMT) protects dopamine (DA) neurons damage through its potent anti-inflammatory effect by inhibiting microglial over-activation and the protection on DA neuron is a dose-dependent response. This invention also discloses that NADPH oxidase plays a critical role of neuroprotection of MMT and MMT therapy for neurodegeneration diseases acts in part through an alternative novel mechanism by reducing microglia-associated inflammation. In addition, this invention reveals that MMT is neurotrophic to DA neurons through the release of neurotrophic factors from astroglia. | 2009-05-07 |
20090118377 | APOGOSSYPOLONE AND THE USES THEREOF - The invention relates to the compound apogossypolone and salts and prodrugs thereof. Apogossypolone functions as an inhibitor of Bcl-2 family proteins. The invention also relates to the use of apogossypolone for inhibiting hyperproliferative cell growth, for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death. | 2009-05-07 |
20090118378 | Technical information for a formula of a natural facial moisturizing cream for daytime use which contains a propylene glycol extract of plant specie solanum tuberosum - This invention relates to facial moisturizing cream used for daytime use in the cosmetics industry; it provides active antioxidants present in the extract of the plant species | 2009-05-07 |
20090118379 | PROCESS FOR THE MANUFACTURE OF A COMPOSITION CONTAINING AT LEAST ONE XANTHOPHYLL - The present invention relates to a process for the manufacture of a composition containing at least one xantophyll selected from the group consisting of lutein and zeaxanthin, said process comprising the steps of: providing an extract of Marigold flower containing the xantophyll(s) in esterified form; saponifying the Marigold flower extract and isolating the xantophyll(s). The process according to the invention is characterized in that the step of saponifying the Marigold flower extract is carried out in the presence of a quaternary ammonium base. | 2009-05-07 |
20090118380 | PROCESS FOR THE PREPARATION OF WATER-IN-OIL AND OIL-IN-WATER NANOEMULSIONS - Process for the preparation of a water-in-oil or oil-in-water nanoemulsion wherein the dispersed phase is distributed in the dispersing phase in the form of droplets having a diameter ranging from 1 to 500 nm, comprising: 1) the preparation of a homogeneous water/oil blend (I) characterized by an interface tension lower than 1 mN/m, comprising water in an amount of 30 to 70% by weight, at least two surface-active agents having a different HLB, selected from non-ionic, anionic, polymeric surface-active agents, said surface-active agents being present in such a quantity as to make the blend homogeneous; 2) the dilution of the blend (I) in a dispersing phase consisting of oil or water with the addition of a surface-active agent, selected from non-ionic, anionic, polymeric surface-active agents, the quantity of the dispersing phase and surface-active agent being such as to obtain a nanoemulsion having a HLB different from that of the blend (I). | 2009-05-07 |
20090118381 | Separation of High Density Lipoproteins on Polymer Monoliths with Decreased Hydrophobicity - Described are polymer monolith compositions for separating high density lipoprotein, as well as related methods of use. | 2009-05-07 |
20090118382 | Ion Exchange Material, Ion Exchange Column, and Production Method - The invention relates to ion-exchange materials comprising a hydrophobic support resin having grafted side chains, wherein the side chains have a surfactant-type structure and comprise ion-exchange groups, and the ion-exchange material is obtainable by radical grafting of the side chains using a radical initiator containing at least one peroxide group. By means of the surfactant-type structure and the specific radical initiator, a regiospecific and particularly uniform arrangement of the side chains on the support resin is achieved which in addition enables outstanding and uniform hydration of the ion-exchange groups. This is expressed, in particular, in improved signal asymmetries for bromide and nitrate. | 2009-05-07 |
20090118383 | PRODUCTION METHOD OF POROUS RESIN BEAD - The present invention provides a method for producing a porous resin bead containing an aromatic vinyl compound-hydroxystyrene-di(meth)acrylate copolymer, the method including: dissolving a monomer mixture containing an aromatic vinyl compound, an acyloxystyrene and a di(meth)acrylate compound, and a polymerization initiator in an organic solvent to obtain a solution containing the monomer mixture and the polymerization initiator; suspending the solution in water in the presence of a dispersion stabilizer; performing a suspension copolymerization to thereby obtain an aromatic vinyl compound-acyloxystyrene-di(meth)acrylate compound copolymer; and hydrolyzing an acyloxy group of the acyloxystyrene monomer component in the copolymer. The porous resin bead produced by the method of the present invention can be suitably used, for example, as a support for solid phase synthesis. | 2009-05-07 |
20090118384 | HYDROPHOBIC AND/OR OLEOPHOBIC OPEN CELL POLYIMIDE ACOUSTIC AND THERMAL INSULATION FOAMS AND METHODS OF MAKING - Provided are methods of treating an open cell polyimide foam product to produce a treated polyimide foam product having a property of repelling water or oil. The method includes the steps of: selecting a polyimide foam product having an external surface area and an open cell structure that has an interior surface area, wetting the exterior surface area and the interior surface area with a chemical treatment fluid comprising a treatment chemical that has a property of repelling water or oil, and distributing the treatment chemical onto at least a portion of the interior surface area sufficient to modify a surface property of the interior surface. Also provided are treated polyimide foam products that have an open cell polyimide foam substrate with an interior surface area and a treatment chemical on at least a portion of the interior surface area. The treatment chemical renders the interior surface hydrophobic or oleophobic. | 2009-05-07 |
20090118385 | Process for Production of Foamed Resin Sheet - The invention provides a process for production of foamed resin sheet which enables satisfactory dispersion of a nucleating agent in a thermoplastic resin and which attains excellent extrusion formability and is excellent in productivity. There is provided a process for production of foamed resin sheet by extruding a thermoplastic resin prepared by incorporating a nucleating agent and a foaming agent consisting of a gas containing at least one of nitrogen and carbon dioxide into a thermoplastic resin, characterized in that the process further comprises incorporating into the thermoplastic resin high molecular weight ester and a wetting agent having a kinematic viscosity coefficient (a kinematic viscosity coefficient at 100° C.; centistokes) of 70 to 2700. | 2009-05-07 |
20090118386 | PROCESS FOR MAKING A POLYURETHANE FOAM - Process for preparing a polyurethane foam, according to the free rise process, the foam having a free rise density of 5-40 kg/m | 2009-05-07 |
20090118387 | Method for Producing Water-Absorbing Polyurethane Foam - A water-absorbing polyurethane foam is produced by reacting, foaming, and curing a raw material which includes aliphatic or alicyclic polyisocyanate, polyester polyol, a polyoxyethylene compound for a hydrophilizing agent, a catalyst and a blowing agent. Thus obtained water-absorbing polyurethane foam has a coating film made from a cured substance of the foam formed on both surfaces. The content of the polyoxyethylene compound in the raw material is 1 to 10 parts by mass with respect to 100 parts by mass in total of the polyester polyol and the polyoxyethylene compound. The raw material is reacted, foamed, and cured at a temperature of 40 to 130° C. The polyisocyanate has an isocyanate index of preferably 85 to 100. | 2009-05-07 |
20090118388 | ENERGY RAY-CURABLE INKJET PRINTING INK - An energy beam curable type ink jet printing ink comprising (A) a colorant, (B) a compound having at least one ethylenically unsaturated bond which can be polymerized by the application of an energy beam and (C) a photopolymerization initiator, wherein
| 2009-05-07 |
20090118389 | Hardenable dental compositions with low polymerization shrinkage - The present invention features a hardenable dental composition that contains: (1) at least one cyclic allylic compound having at least one sulfur atom in the ring, and (2) at least one at least one ethylenically unsaturated compound, such as a substituted (meth)acryloyl compound. The compositions also typically comprise an initiator system, preferably a photoinitator system containing at least 0.08 wt-% of one or more photosensitizers. | 2009-05-07 |
20090118390 | ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE ARTICLES AND METHODS OF FORMING ULTRA HIGH MOLECULAR WEIGHT POLYETHYLENE ARTICLES - The present invention generally provides implantable articles and methods of forming implantable articles from a crosslinked ultrahigh molecular weight polyethylene (“UHMWPE”) blend stabilized with Vitamin E. The crosslinked UHMWPE blend may be prepared by combining the UHMWPE material and vitamin E prior to irradiating the UHMWPE blend with electron beam radiation at a sufficient radiation dose rate to induce crosslinking. The crosslinked UHMWPE blend may be incorporated into a variety of implants, and in particular, into endoprosthetic joint replacements | 2009-05-07 |
20090118391 | CHEMICALLY-CURING TYPE GLASS IONOMER CEMENT - This invention provides quality and safe chemically-curing type GIC that solves all the disadvantages of light-curing type GIC, and has mechanical strength not lower but higher than that of light-curing type GIC and, in addition to this, the original features and advantages of GIC. The chemically-curing type glass ionomer cement according to the present invention includes porous and particulate hydroxy apatite that has a means diameter of not less than 0.6 μm and less than 100 μm and a large specific surface, and is added and mixed into the glass ionomer cement. | 2009-05-07 |
20090118392 | CHEMICAL DERIVATIZATION OF SILICA COATED FULLERENES AND USE OF DERIVATIZED SILICA COATED FULLERENES - This invention is directed to a new composition of matter in the form of chemically derivatized silica coated fullerenes, including silica coated C | 2009-05-07 |
20090118393 | Method of preparing thermoplastic resin having superior gloss, impact strength and whiteness - Disclosed is a method for preparing a thermoplastic resin with superior impact resistance, chemical resistance and processability as well as excellent gloss and whiteness. The method includes emulsion-polymerizing a conjugated diene compound monomer to prepare a rubber latex having an average particle diameter of 1,800 Å to 5,000 Å, a polymerization conversion ratio of at least 90% and a swelling index of 12 to 40, an average gel content of 70 to 95%, emulsion-polymerizing 45 to 75 parts by weight of the rubber latex with 17 to 40 parts by weight of an aromatic vinyl compound and 4 to 20 parts by weight of a vinyl cyanide compound to prepare a graft copolymer latex, and coagulating the graft copolymer latex with a coagulant at 60 to 80° C., and aging the graft copolymer latex at 80 to 99° C. to obtain a graft copolymer powder. | 2009-05-07 |
20090118394 | PROCESS FOR THE PRODUCTION OF IMPACT-MODIFIED FILLED POLYCARBONATE COMPOSITIONS - The present invention relates to a process for the production of impact-modified filled polycarbonate compositions and molding compositions. A process of the present invention involves: (i) mixing the CNT (component C) with rubber-containing vinyl copolymer (component B) and/or rubber-free vinyl copolymer (component D) on a twin screw extruder, to obtain a CNT masterbatch, (ii) mixing the CNT masterbatch with polycarbonate (component A) and optionally with Component B and/or Component D and optionally with an additive on a twin screw extruder. A polycarbonate composition prepared according to the present invention does not experience degradation of the molecular weight of the polycarbonate during compounding a compared to processes known in the art. | 2009-05-07 |
20090118395 | PROCESS OF POLYMER MODIFIED ASPHALT PREPARATION - A process of preparing a polymer modified asphalt (PMA) comprising mixing a predetermined amount of a polymer-asphalt master batch with a predetermined amount of an asphalt-cross linking agent blend. The polymer-asphalt master batch comprises at least one polymer and a first asphalt. The asphalt-cross linking agent blend comprises a second asphalt and at least one cross linking agent. A predetermined amount of the polymer-asphalt master batch is blended with a predetermined amount of the asphalt-cross linking agent blend to form a PMA blend. Mixing of the PMA blend is performed without substantial delay following blending of the polymer-asphalt master batch with the asphalt-cross linking agent blend. | 2009-05-07 |
20090118396 | PROCESS TO MANUFACTURE WOOD FLOUR AND NATURAL FIBERS TO ENHANCE CELLULOSIC PLASTIC COMPOSITES - A process for combining wood flour with one or more natural fibers into a mixture subsequently used in making NFPC thermoplastic and thermoset composites. The process involves blending the wood flour and natural fibers with the resulting mixture containing from between 5%-95% natural fibers. After blending, the resultant mixture goes through one or more stages in which particles in one range of sizes are separated out from particles having a different range of sizes. The separated mixture is packaged and the contents subsequently being used in making the NFPC composites by mixing thermoplastics or thermoset materials with upwards of 50% of the wood flour and natural fiber material blend. | 2009-05-07 |
20090118397 | Waterborne Film-Forming Compositions Containing Reactive Surfactants and/or Humectants - The present invention is directed to aqueous coating compositions, such as paints, containing a film-forming latex polymer and a reactive surfactant. The reactive surfactant, a polyglycerol ester or ether of an unsaturated fatty acid, reduces or eliminates the need for traditional water-soluble additives that lower the water resistance of the dry coating. Additionally, the reactive surfactants of the invention are capable of oxidative cross-linking during the curing process, forming a dry film that is more durable and water-resistant than traditional latex paint composition. | 2009-05-07 |
20090118398 | Material to be injection molded, process thereof, and use therefore - The present invention refers to an adequate composite material to be prepared by an injection process and to an injection process of a composite material. In accordance with the process of the present invention, the composite material is prepared by carrying out the steps of (i) making the length of the natural fibers uniform; (ii) treating the surface of the natural fibers and of the lignocellulosic residues, if present; (iii) premixing the components of the composite; (iv) extruding and granulating the composite material; and (v) injection molding the material of the composite for the conformation of the parts. | 2009-05-07 |
20090118399 | Delivery System For Releasing Silicone Ingredients - A solid composition for releasing active silicone ingredients contains a cationic polymer, an active silicone ingredient and optionally a thickener and a carrier. The cationic polymer is preferably a homopolymer or a copolymer. The cationic polymer has higher water solubility at neutral pH than at a basic pH of 9-11. Granular encapsulated compositions can be prepared by using the solid silicone-releasing composition as a component in a laundry detergent powder, tablet or bar. This is particularly of interest for the delivery of silicone ingredients in the rinse cycle of a laundry operation. | 2009-05-07 |
20090118400 | RESIN COMPOSITION - A resin composition comprising alicyclic structure-containing polymer such as additional copolymer with monomer having norbornene structure and ethylene, hydrogenated product of ring-opening polymer with monomer having norbornene structure, and aromatic ring-hydrogenated product of copolymer with styrene and isoprene; and piperidine derivatives such as N,N′-bis(2,2,6,6-tetramethyl-4-piperidyl)-N,N′-diformyl-hexamethylenediamine and 4-(formyl amino)-2,2,6,6-tetramethyl piperidine. | 2009-05-07 |
20090118401 | Curable Composition - Firstly, disclosed is a curable composition which includes an organic polymer containing a crosslinkable silyl group, an ultraviolet ray absorbing agent having a triazine skeleton and a hindered amine based light stabilizer, and thereby, exhibits improved weather resistance both in a thin layer portion and in a thick layer portion. Secondly, disclosed is a curable composition which includes an organic polymer containing a crosslinkable silyl group, a (meth)acrylic polymer containing an epoxy group, a divalent tin organic carboxylate and an organic amine compound, and thereby, exhibits excellent weather resistance, anti-staining property, restoring property and durability. Thirdly, disclosed are an excellent curable composition which includes a reactive organic polymer containing at least one crosslinkable silyl group in one molecule thereof, a reactive organic polymer containing less than one crosslinkable silyl group in one molecule thereof, and thermally expandable hollow spheres as essential components, and thereby, exhibits economical productivity, good physical properties, safety and fire resistance; and a sealing material produced from the curable composition. Further, disclosed is a method for forming a fire-resistant structure with ease and at a low cost. | 2009-05-07 |